most recent analyst report on biota?, page-8

The Bioshare analyst summed it up pretty well way back in April and market activity since April agreed with him.


This part is interesting
"What is apparent about the Australia-US biotech capital pathway is that the ASX has proven to be an attractive stock exchange for some US companies and that the Nasdaq largely has not been an exchange that has proven to be beneficial for Australian life science
firms."

Maybe the US company BOTA (Biota Pharmaceuticals) should dual list on the ASX given it is an attractive exchange for some US companies!